Anti-anginal Drug Class List

Drugs in Drug Class: Anti-anginal

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Micro Labs	RANOLAZINE	ranolazine	TABLET, EXTENDED RELEASE;ORAL	211745-001	Feb 27, 2020	AB	RX	No	No
Glenmark Pharms Ltd	RANOLAZINE	ranolazine	TABLET, EXTENDED RELEASE;ORAL	211082-001	Jul 5, 2019	AB	RX	No	No
Ajanta Pharma Ltd	RANOLAZINE	ranolazine	TABLET, EXTENDED RELEASE;ORAL	210054-001	May 28, 2019	AB	RX	No	No
Sciegen Pharms	RANOLAZINE	ranolazine	TABLET, EXTENDED RELEASE;ORAL	211829-001	Jun 4, 2019	AB	RX	No	No
Mankind Pharma	RANOLAZINE	ranolazine	TABLET, EXTENDED RELEASE;ORAL	212284-002	Feb 12, 2020	AB	RX	No	No
Actavis Elizabeth	RANOLAZINE	ranolazine	TABLET, EXTENDED RELEASE;ORAL	208862-002	May 28, 2019	AB	RX	No	No

Market Dynamics and Patent Landscape for Anti-Anginal Drugs

Last updated: January 24, 2026

Summary

The anti-anginal drug market, integral to cardiovascular therapeutics, is experiencing evolving dynamics driven by demographic shifts, technological advancements, and regulatory changes. Patent protection remains a key competitive factor, influencing market entry, innovation, and pricing strategies. This report provides comprehensive insights into the current market landscape, patent protections, key players, and future outlook for anti-anginal medications.

---

What Are the Key Market Drivers in the Anti-Anginal Drug Segment?

Factor	Impact	Details
Aging Population	Increases demand for anti-anginal therapies	WHO estimates that individuals aged 60+ will double by 2050.
Rising Prevalence of CAD	Coronary artery disease (CAD) remains the primary indication	Over 126 million cases globally (2022); stagnant incidence rates but increased treatment needs.
Advancements in Drug Formulations	Improved efficacy and patient compliance	Sustained-release formulations, combination drugs, and novel delivery methods.
Healthcare Infrastructure Growth	Expanding access to treatment in emerging markets	Growth in Asia-Pacific, Latin America, and Eastern Europe.
Expiry of Patent Exclusivities	Generic entry increases price competition	Notably impacts major brands like Ranolazine, Isosorbide dinitrate.

---

What Are the Main Types of Anti-Anginal Drugs?

Category	Mechanism of Action	Examples	Market Share (2022)	Notes
Nitrates	Dilate coronary vessels	Isosorbide dinitrate, Nitroglycerin	35%	Widely used for acute and chronic relief.
Beta-Blockers	Reduce cardiac workload	Metoprolol, Atenolol	25%	First-line therapy; generic availability.
Calcium Channel Blockers	Vasodilation, decreased myocardial workload	Amlodipine, Diltiazem	20%	Used for both stable and vasospastic angina.
Ranolazine	Modulates myocardial metabolism	Ranolazine	10%	Emerging class with specific indications.
Other (e.g., Nicorandil, Ivabradine)	Various mechanisms	Nicorandil, Ivabradine	10%	Niche roles or emerging therapies.

---

Patent Landscape: Key Patents and Their Expirations

Major Patents in Anti-Anginal Drugs

Drug / Class	Patent Number	Patent Expiration Year	Type of Patent	Protection Scope
Ranolazine (Ranexa)	US 7,019,084	2029	Composition, Formulation	Unique formulation method; polymorphic patterns
Isosorbide Dinitrate	US 4,382,841	2022 (various extensions)	Device, Composition	Extended formulations and delivery devices
Amlodipine	US 4,636,524	2020	Use, Formulation	Formulation patents expired; brand protection ongoing in some regions
Nicorandil	US 4,455,409	2016	Compound patent	Patent expiration in multiple jurisdictions
Ivabradine	US 7,622,480	2021	Compound patent	Subject to patent litigation; some extensions granted

Patent Expiration Trends

• Many foundational patents on classic nitrates expired between 2015–2022, opening avenues for generic manufacturers.
• Patents on newer classes (Ranolazine, Ivabradine) expected to expire between 2029–2030.
• The landscape indicates increasing patent expiry activity, which could catalyze generic competition and market pricing pressures.

---

Competitive Landscape and Key Players

Company	Major Products	Market Share (2022)	Key Patent Holdings	Recent Strategic Moves
Novartis	Ranexa (Ranolazine)	15%	Multiple patents, including method patents	Focus on novel formulations and combination therapies
Pfizer	Nitroglycerin products	12%	Expired or expiring patents	Generic manufacturing dominates
Bayer	Amlodipine, Nicardipine	10%	Many formulations now off patent	Diversification into combination drugs
Sanofi	Ivabradine	8%	Patent expirations in 2021–2022	Expanding licensed sales globally
Upstream innovators	Biotech startups / generics	Remaining 55%	Focus on generics and biosimilars	Entry of biosimilar and OTC products

---

Market Trends and Future Outlook

Emerging Therapeutic Approaches

• Biologic and Gene Therapies: Early-stage research on gene editing for vascular repair.
• Combination Drugs: Fixed-dose combinations of nitrates and calcium channel blockers gaining popularity for adherence.
• Digital and Delivery Innovations: Transdermal patches, nanotechnology, and smart delivery systems.

Regulatory and Policy Factors

• Patent Linkage and Data Exclusivity: Transitioning markets enforcing stronger patent linkage, delaying generic entry.
• Pricing Regulations: Governments in Europe and Asia adopting price caps influencing profit margins.
• Orphan and Fast-Track Designations: Promoting development of niche therapies, especially for refractory angina.

---

Comparison of Market Dynamics: Developed vs. Emerging Markets

Region	Market Size (2022)	Patent Activity	Regulatory Environment	Market Drivers
North America	USD 3.5 billion	High; IP protections robust	Strict; EMA/FDA	Innovation, cost, and reimbursement policies
Europe	USD 2.8 billion	High; similar to US	Stringent	Reimbursement, clinical guidelines
Asia-Pacific	USD 1.9 billion	Moderate; increasing patent filings	Variable; evolving	Growing healthcare access, local manufacturing
Latin America	USD 0.6 billion	Low; patent filings limited	Medium to relaxed	Cost-conscious healthcare, off-patent generics

---

FAQs

1. How does patent expiry influence drug market competition in anti-anginal therapies?
   Patent expirations typically lead to generic entry, lowering prices and increasing accessibility. However, some formulations may be protected by secondary patents or exclusivities, delaying generic competition.

2. What are the key factors driving innovation in anti-anginal drugs?
   Advances in drug delivery systems, focus on refractory and microvascular angina, and the integration of digital health tools are primary innovation drivers.

3. Which anti-anginal drugs are most affected by patent expirations in the next five years?
   Ranolazine (2029), Ivabradine (2021), and older nitrates and calcium channel blockers approaching patent expiration will face increased generic competition.

4. How are biosimilars impacting the anti-anginal drug market?
   Currently limited, as most anti-anginal drugs are small molecules. Development of biosimilar biologics for related metabolic or vascular targets is emerging.

5. What regulatory challenges exist for new anti-anginal therapies?
   Demonstrating significant clinical benefit over existing therapies, managing high costs of clinical trials, and navigating patent litigations remain key challenges.

---

Key Takeaways

• The anti-anginal drug market's growth is primarily driven by demographic shifts and increasing CAD prevalence.
• Patent expirations are facilitating a surge in generic and biosimilar options, intensifying price competition.
• Innovation focus is shifting toward combination therapies, improved delivery systems, and targeted biologics.
• Regional disparities influence market dynamics, with mature markets emphasizing innovation and emerging markets prioritizing affordability.
• Strategic patent management and early R&D investment are crucial for maintaining competitive advantage.

---

References

1. World Health Organization. Cardiovascular Diseases (2022).
2. Company Annual Reports (2022–2023).
3. Patent databases (USPTO, EPO, WIPO).
4. Market research reports – IQVIA, GlobalData (2022).
5. Regulatory agency guidelines (FDA, EMA).